Caplin Point Laboratories Ltd (CAPLIPOINT)
₹1356.45▲0.81%
Caplin Point Laboratories Ltd share Performance
- ₹1345.4₹1363.45₹1356.45
0.81%
Low
Day's Volatility:1.33%
High
0.52%
- ₹673₹1619.05₹1356.45
50.39%
Low
52 Weeks Volatility:69.74%
High
19.36%
| Returns % | |
| 1 Month Return | -1.12 % |
| 3 Month Return | -3.13 % |
| 1 Year Return | 98.09 % |
| Market Stats | |
| Previous Close | ₹1,345.50 |
| Open | ₹1,347.00 |
| Volume | 37.38K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹10,301.12Cr |
Analyst Rating
based on 3 analysts
Based on 3 analysts offering long term price targets for Caplin Point Laboratories Ltd. An average target of ₹1579.33
Source: S&P Global Market Intelligence
Company Information
Share Price: ₹1356.45 per share as on 30 Apr, 2024 04:01 PM
Market Capitalisation: ₹10,301.12Cr as of today
Revenue: ₹435.50Cr as on December 2023 (Q4 23)
Net Profit: ₹119.82Cr as on December 2023 (Q4 23)
Listing date: 23 Jun, 2014
Chairperson Name: C C Paarthipan
| Organisation | Caplin Point Laboratories Ltd |
| Headquarters | Chennai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Caplin Point Laboratories Ltd
Asit C Mehta Recommends Accumulating Caplin Point Laboratories - 29 Apr, 2024
Asit C Mehta recommends accumulating Caplin Point Laboratories with a target price of Rs 1,675 based on FY26E EPS of Rs 83.7 and a forward PE valuation multiple of 20. The company produces and exports generic formulations and branded products to overseas markets.
Caplin Point Laboratories Continues Growth Path - 20 Apr, 2024
Caplin Point Laboratories' end-to-end model has served it well in Latin American markets, which accounted for 85% of its revenues in 9MFY24. The company's subsidiary, Caplin Steriles, is experiencing high growth in regulated markets. Caplin Point is expanding capacity with an outlay of ₹830 crore.
Caplin Point Subsidiary Receives FDA Approval - 16 Apr, 2024
Caplin Point Laboratories' subsidiary, Caplin Steriles, has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution. The solution is used to treat eye infections caused by conjunctivitis and corneal ulcers.
Insiders Receive 70% Cut as Caplin Point Laboratories Market Cap Increases - 02 Apr, 2024
Caplin Point Laboratories' market cap has increased by ₹7.8b, with insiders receiving a 70% cut. The company's significant insider control implies vested interests in growth, with three investors holding a majority stake of 55%. Ownership research can provide insight into opportunities for the stock.
Fundamentals of Caplin Point Laboratories Ltd
Insights on Caplin Point Laboratories Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 14 quarters, 269.88 Cr → 452.7 Cr (in ₹), with an average increase of 3.9% per quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CAPLIPOINT has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 2.83% to 3.32% in Mar 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 9 quarters, 74.95 Cr → 117.2 Cr (in ₹), with an average increase of 5.4% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, CAPLIPOINT has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 0.41% to 1.06% in Mar 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 70.62% of holdings in Mar 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 1 month, CAPLIPOINT stock has moved down by -1.1%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 26.10% to 24.95% in Mar 2024 quarter
Caplin Point Laboratories Ltd Valuation
Caplin Point Laboratories Ltd in the last 5 years
Lowest (6.76x)
March 24, 2020
Today (23.53x)
April 30, 2024
Industry (62.57x)
April 30, 2024
Highest (34.97x)
February 15, 2018
Shareholding Pattern
| Investors | Holdings % | Prev. 1 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 70.62% | 0.00 | |
| Foreign Institutions | 3.32% | 0.00 | |
| Mutual Funds | 1.06% | 0.00 | |
| Retail Investors | 24.95% | 0.00 | |
| Others | 0.04% | 0.00 |
Technicals of Caplin Point Laboratories Ltd share
News & Events of Caplin Point Laboratories Ltd
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Caplin Point Laboratories Ltd shares.
Caplin Point Laboratories Ltd (CAPLIPOINT) share price today is ₹1356.45
Caplin Point Laboratories Ltd is listed on NSE
Caplin Point Laboratories Ltd is listed on BSE
- Today’s highest price of Caplin Point Laboratories Ltd is ₹1363.45.
- Today’s lowest price of Caplin Point Laboratories Ltd is ₹1345.4.
PE Ratio of Caplin Point Laboratories Ltd is 23.53
PE ratio = Caplin Point Laboratories Ltd Market price per share / Caplin Point Laboratories Ltd Earnings per share
Today’s traded volume of Caplin Point Laboratories Ltd(CAPLIPOINT) is 37.38K.
Today’s market capitalisation of Caplin Point Laboratories Ltd(CAPLIPOINT) is ₹10301.12Cr.
| Caplin Point Laboratories Ltd(CAPLIPOINT | Price |
|---|---|
52 Week High | ₹1619.05 |
52 Week Low | ₹673 |
Caplin Point Laboratories Ltd(CAPLIPOINT) share price is ₹1356.45. It is down -16.22% from its 52 Week High price of ₹1619.05
Caplin Point Laboratories Ltd(CAPLIPOINT) share price is ₹1356.45. It is up 101.55% from its 52 Week Low price of ₹673
| Caplin Point Laboratories Ltd(CAPLIPOINT | Returns |
|---|---|
1 Day Returns | 10.95% |
1 Month Returns | -1.12% |
3 Month Returns | -3.13% |
1 Year Returns | 98.09% |